ANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord Genuity
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)‘s stock had its “buy” rating reissued by Canaccord Genuity in a research note issued to investors on Thursday.
Several other equities research analysts also recently commented on ANIP. BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $67.33.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The business had revenue of $48.16 million for the quarter, compared to the consensus estimate of $48.12 million. During the same period last year, the company earned $1.09 EPS. The firm’s revenue was up 25.0% compared to the same quarter last year.
Several hedge funds and other institutional investors have recently modified their holdings of ANIP. BNP Paribas Arbitrage SA lifted its position in shares of ANI Pharmaceuticals by 44.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 664 shares during the period. Municipal Employees Retirement System of Michigan lifted its position in shares of ANI Pharmaceuticals by 132.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $197,000 after purchasing an additional 2,390 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $204,000. Stevens Capital Management LP acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $207,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $210,000. Hedge funds and other institutional investors own 55.96% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.